ecancer

ecancer.org

ecancer is a UK charity which provides accessible, high-quality educational content, free to the global oncology community. Our mission is to raise the standards of care for cancer patients across the world through education.

 

ecancer
H

Lecture Summary - ASCO 2022 Sacituzumab Govitecan Provides Clinically Meaningful PFS Benefit for HR+/HER2- mBC

By ecancer FEATURING Hope Rugo
By ecancer FEATURING Hope Rugo
5 views
June 29, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

Featured Video

20:09
AstraZeneca Oncology

Management Strategies for Anemia in First-line Maintenance Therapy f…

Feat. D. Czel, C. Arn
ASCO 2022
03:59
ecancer

Lecture Summary - ASCO 2022 Sacituzumab Govitecan Provides Clinicall…

Feat. H. Rugo
21:43
ecancer

ASCO 2022 on the Latest Developments in mHSPC and mCRPC

Feat. H. Payne, K. Chi, K. Miller, L. Krabbe
10:12
ecancer

ASCO 2022: ASCO and WHO to Collaborate on Quality Indicators for Can…

Feat. A. Ilbawi
05:50
ecancer

ASCO 2022 on the rEECur Trial: High-Dose Ifosfamide as a SoC for Rec…

Feat. M. Mccabe
06:54
ecancer

ASCO 2022: Head & Neck Cancer Highlights

Feat. M. Persky
07:33
ecancer

ASCO 2022: Dabrafenib + Trametinib Significantly Increases Overall R…

Feat. E. Bouffet
28:07
ecancer

ASCO 2022: Latest Updates in Prostate Cancer, Including PARPi

Feat. E. Efstathiou, C. Sternberg, N. Shore, P. Cornford
08:05
ecancer

ASCO 2022 ctDNA Analyses of the Phase III VOYAGER Trial: KIT Mutatio…

Feat. C. Serrano
05:57
ecancer

ASCO 2022 on E2211 Trial for Advanced Pancreatic Neuroendocrine Tumo…

Feat. P. Kunz
21:40
ecancer

ASCO 2022 Panel Discussion on Current Strategies and Trials on Bladd…

Feat. P. Grivas, R. Jones, P. Cornford, K. Miller
04:07
ecancer

ASCO 2022: Single-Agent PD-1 Blockade as Curative-Intent Treatment i…

Feat. A. Cercek
06:00
ecancer

ASCO 2022 on a Phase II S1800A Trial: Ramucirumab + Pembrolizumab Im…

Feat. R. Herbst
20:12
ecancer

ASCO 2022 on the Latest Updates in EGFR+ NSCLC

Feat. B. Besse, A. Minchom, A. Passaro, E. Felip
03:17
ecancer

ASCO 2022: N-803 + BCG Combination Shows Promising Results in BCG-Un…

Feat. K. Chamie
06:32
ecancer

Primary Results of the Phase III SHINE Study: Ibrutinib in Combinati…

Feat. M. Wang
05:00
ecancer

ASCO 2022 on the Adjuvant Endocrine Therapy for ER+/HER2- Breast Can…

Feat. E. Brain
07:14
ecancer

ASCO 2022 Sacituzumab Govitecan Provides Clinically Meaningful PFS B…

Feat. H. Rugo
07:25
ecancer

Updated Data From the Phase 1/2 MajesTEC-1 Study: Evaluating Teclist…

Feat. A. Nooka
06:05
ecancer

ASCO 2022 LUMINA Study Updates: Biomarker Guidance Allows Patients 5…

Feat. T. Whelan
06:17
ecancer

ASCO 2022 Phase III EVEREST Study Updates: Everolimus After Surgery …

Feat. C. Ryan
05:33
ecancer

ASCO 2022 ctDNA Analysis Can Help Identify the Need for Adjuvant The…

Feat. J. Tie
03:36
ecancer

ASCO 2022 Panitumumab + mFOLFOX6 Improves OS for RAS Wild-Type Left-…

Feat. T. Yoshino
12:04
ecancer

ASCO 2022: Breast Cancer Highlights

Feat. M. Lambertini
01:57
ecancer

Lecture Summary - ASCO 2022 CheckMate 9ER: aRCC pts on Nivolumab + C…

Feat. C. Suárez
04:05
ecancer

ASCO 2022 Momelotinib Superior to Danazol in Symptomatic and Anaemic…

Feat. R. Mesa
03:54
ecancer

ASCO 2022 Biomarker Analysis of the NeoALTTO Trial Provides Oncofert…

Feat. M. Lambertini
09:52
ecancer

ASCO 2022 ATHENA–MONO Phase III Trial to Evaluate Rucaparib Monother…

Feat. B. Monk
05:57
ecancer

ASCO 2022 DESTINY-Breast04: Trastuzumab Deruxtecan vs. Treatment of …

Feat. S. Modi
05:41
ecancer

ASCO 2022 DESTINY-Breast04: Trastuzumab Deruxtecan Doubles PFS in MB…

Feat. S. Modi